
Login
Who's Online
We have 641 guests and no members online
Statistics
- Users 5531
- Articles 742
- Articles View Hits 17312253
Why Use This Site for Advertisement?
Thank you for your interest in advertising on Gene Therapy Net. The website is active since January 2008 and the site's traffic grows day by day (see statistics). The visitors of Gene Therapy Net are professionals, doctors and researchers, as well as students, patients, regulatory affairs officers, government policy officers, and everyone else interested in gene therapy. |
|
Gene Therapy Net is run by a policy officer in the clinical gene therapy trial assessment procedure in the Netherlands. He has a scientific background in molecular biology and immunology. The website is a non-governmental, personal initiative and is aimed to provide comprehensive and accurate information about gene therapy, clinical trials, research news, and relevant gene therapy regulation and legislation. |
Advertisement Opportunities
Full banners, cube banners and text ads will be placed on highly visible sections throughout the site. Cube banners and text ads are placed in the left columns of the site, whereas full banners are placed in the middle wide column of the site. Your banner or text ad will be hyperlinked to the web address of your choice.
There are four different types of campaigns:
1 | Full banner | Located in rotation with other banners on all pages, including the home page |
2 | Home page banner or text links | Located only on the home page. Always visible in 1st or 2nd news item in center of the home page |
3 | Cube banner | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
4 | Text links | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
Advertisement Rates
We suggest a minimum of 3 months or at least 10,000 impressions, but please keep in mind that these rates and time lengths are not set in stone, but rather displayed to give you an idea on how our ad pricing is usually structured. By advertising on Gene Therapy Net, you agree to our terms and conditions listed below.
Contact us for more information about advertising.
Advertising Terms and Conditions: All ads are reviewed for correct usage, and must be approved prior to publication. Gene Therapy Net reserves the right to refuse advertising privileges to any web site for any reason, including the promotion of pornographic products and/or content, the advocating of illegal activities, immoral conduct, plagiarism, cheating, etc. Gene Therapy Net shall not be held responsible for grammatical errors, typographical errors, or errors in artwork provided by the advertiser. All ads are at the discretion of Gene Therapy Net. All rates are agreed on before advertisement is placed. Your ad will be place after full payment has been received. When an order has been received and payment taken for the service there will be no refund to the advertiser. Gene Therapy Net reserves the right to modify, change or otherwise improve upon the design and format of any or all of its pages at any time without notice. Gene Therapy Net reserves the right to modify, eradicate and/or change any or all of these terms and conditions without notice, including the right to change the above rates or to terminate this advertising program. We appreciate, but do not require, reciprocal links to Gene Therapy Net to be posted on your site.
Suggestions
Gene Therapy News
- Battling Bladder Cancer: New Gene Therapy to The Rescue - WALB
Wed, 12 Feb 2025 19:25:0 GMT - What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing - ProPublica
Wed, 12 Feb 2025 14:00:0 GMT - Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Wed, 12 Feb 2025 13:54:0 GMT - GenSight’s Optic Neuropathy gene therapy sustains efficacy over five years - Clinical Trials Arena
Wed, 12 Feb 2025 13:45:0 GMT - Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - StockTitan
Wed, 12 Feb 2025 13:42:0 GMT - CSL Behring announces four-year results for haemophilia B gene therapy Hemgenix - PMLiVE
Wed, 12 Feb 2025 13:30:3 GMT - Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD - The Manila Times
Wed, 12 Feb 2025 13:24:2 GMT - Voyager updates on SOD1 ALS gene therapy program - The Pharma Letter
Wed, 12 Feb 2025 12:03:4 GMT - Middle East & Asia Pacific Cell and Gene Therapy Market Growth, - openPR
Wed, 12 Feb 2025 10:19:0 GMT - GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study - The Bakersfield Californian
Wed, 12 Feb 2025 07:30:1 GMT - GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study - Joplin Globe
Wed, 12 Feb 2025 07:30:1 GMT - One shot to lower cholesterol for life? Scientists unlock a groundbreaking gene therapy - News-Medical.Net
Wed, 12 Feb 2025 00:31:0 GMT - Off-target effects force Voyager to rethink ALS gene therapy design - FirstWord Pharma
Tue, 11 Feb 2025 21:49:2 GMT - Battling bladder cancer: New gene therapy offers hope - WPSD Local 6
Tue, 11 Feb 2025 16:58:0 GMT - Journey of Voyager’s ALS gene therapy to clinic hindered by need to find alternative payload - Fierce Biotech
Tue, 11 Feb 2025 16:27:2 GMT